| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 |
Form 4: Grossman Adam S, Director
Received 105,000 shares by exercise or conversion ($567K) · Sold 147,000 shares ($1.76M) |
| 05 Nov 2026 | 144 |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year |
| 07 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year |
| 28 Jul 2026 |
Form 4: Kestenberg-Messina Kaitlin M., COO and SVP, Compliance
Gave up 3,177 shares to cover exercise price or tax ($26.6K) |
| 17 Jul 2026 |
Form 4: Kohler Terry, CFO and Treasurer
Received 85,130 shares as a grant or award · Granted 136,363 Stock Option (Right to Buy) |
| 02 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
ADMA Biologics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 2, 2026. At the Annual Meeting, the following matters were submitted to a vote of stockholders: |
| 28 May 2026 |
Form 4: Grossman Jerrold B, Director
Bought 6,400 shares ($50.6K) |
| 14 May 2026 |
Form 4: Grossman Jerrold B, Director
Bought 12,500 shares ($100K) |
| 12 May 2026 |
Form 4: Grossman Jerrold B, Director
Bought 12,500 shares ($100K) |
| 06 May 2026 | 10-Q |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year |
| 04 May 2026 |
8-K: Other Events
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIVTM to Include Pediatric Immune Compromised Patients Two Years of Age and Older |
| 29 Apr 2026 | SCHEDULE 13G |
| 15 Apr 2026 | ARS |
| 15 Apr 2026 | DEFA14A |
Loading...